Background: Wasp bite is an important occupational hazard in Nepal. Almost 25% of the victims die. This study aimed to identify the demographics, clinical presentation, hospital course and outcome of wasp bite victims in a referral hospital in Nepal.
Methods: A retrospective study was conducted in Tribhuvan University Teaching Hospital, Kathmandu. Medical records of patients admitted for wasp bite between January 2008 and December 2012 were reviewed. Demographic, clinical and laboratory data were collected and their effects on outcomes in the form of death, duration of hospitalization, number of dialysis sessions and time to resolution of oliguria were analyzed.
Results: All 18 patients came from rural areas, 13 (72%) were farmers, mean age was 39.6 ±16.7 years (range 7 to 69). Most bites occurred between August and November. Oliguria, vomiting, red urine and jaundice were the main presenting symptoms; oliguria developed within 48 hours of bite in 17 (94 %) cases. Nine patients (50%) required blood transfusion. All developed acute renal failure (ARF) and required dialysis, mean hemodialysis session being 7.4±5.3 (range 1 to 20). Sixteen patients (89 %) received steroid for presumed interstitial nephritis. One patient expired. Mean time to resolution of oliguria was 15.9±9.5 days (range 2 to 35). Mean hospital stay was 18.7±13.4 days (range 1 to 46), those having higher number of bites had longer stay.
Conclusions: Wasp bite mostly affects farmers of working age in rural Nepal. Hemolysis and acute renal failure are two important complications. Timely dialysis in established acute renal failure and steroid in suspects of interstitial nephritis improves survival.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Safety of 1 mcg/mL as the starting dose in cluster protocol for hymenoptera immunotherapy.
Allergol Immunopathol (Madr)
January 2025
Department of Allergy and Clinical Immunology, Firooz Abadi Hospital, Iran University of Medical Sciences, Tehran, Iran;
Background: Hymenoptera venom allergy is a potentially severe allergic reaction in the general population. The only preventative approach in these cases is venom immunotherapy (VIT), which follows different protocols. The recommended initial dose is 0.
View Article and Find Full Text PDFHymenoptera venom allergy in children.
Ital J Pediatr
December 2024
Department of Health Sciences, University of Florence, Florence, 50139, Italy.
From a taxonomic point of view, Hymenoptera are subclassified into families: Apidae, including honeybees (Apis mellifera) and bumblebees (Bombus), and Vespidae, which, in turn, are divided into the subfamilies of Vespinae (wasps, including hornets, vespules, dolichovespules) and Polistinae (paper wasp). Hypersensitivity to Hymenoptera venom can be linked to immunological (IgE-mediated or non-IgE-mediated) and non-immunological mechanisms. Reactions are classified into local reactions, large local reactions, systemic reactions, toxic reactions, and unusual reactions.
View Article and Find Full Text PDFComparative Assessment of the Allergenicity of Hyaluronidases from (Pol d 2), (Ves v 2), and Venom (Api m 2).
Toxins (Basel)
November 2024
Center of Allergy and Environment (ZAUM), Technical University of Munich, School of Medicine and Health & Helmholtz Munich, German Research Center for Environmental Health, 85764 Munich, Germany.
Article Synopsis
- * Key allergens evaluated include hyaluronidases from honey bee (Api m 2), European paper wasp (Pol d 2), and yellow jackets (Ves v 2.0101 and Ves v 2.0201), with sensitization rates among patients varying significantly.
- * Results show that individuals primarily sensitized to Api m 2 have minimal cross-reactivity with other venoms, while those sensitized to other allergens may react to Api m 2, emphasizing the importance of identifying the primary allergen for effective
Health-Related Quality of Life in Jack Jumper Ant Venom Allergy: Validation of the Venom-Allergy Quality of Life Questionnaire.
J Allergy Clin Immunol Pract
January 2025
Allergy & Immunology, Monash Health, Clayton, Melbourne, Victoria, Australia; Department of Medicine, Monash University, Clayton, Melbourne, Victoria, Australia.
Background: We assessed health-related quality of life (HRQoL) in patients with allergy to the venom of the jack jumper ant (JJA), Myrmecia pilosula, a Hymenoptera order species native and endemic to the Southeastern quarter of Australia. To our knowledge, this has not previously been studied despite an estimated population prevalence of generalized allergic symptoms as high as 3% in some areas.
Objective: To validate the Venom Quality of Life Questionnaire (VQLQ) HRQoL instrument, which was previously validated in patients with wasp and bee venom allergy, for use in this specific ant venom-allergic population.
Bee/Vespula Venom-Specific IgE Ratio Greater Than 5:1 Indicates Culprit Insect in Double-Sensitized Patients.
J Allergy Clin Immunol Pract
January 2025
Department of Dermatology, Venereology, and Allergology, University Hospital Würzburg, Würzburg, Germany. Electronic address:
Background: Venom-allergic patients are frequently double-sensitized to honeybee venom (BV) and Vespula venom (VV). Genuine double allergy is uncommon.
Objectives: To assess whether a quantitative comparison of BV- and VV-specific IgE levels permits an identification of the culprit venom in double-sensitized patients, and to evaluate whether independent sensitization to BV- and VV-specific components corresponds to an indication for double immunotherapy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!